인비비드 IVVD 주가

핵심 리스크

특이 리스크 신호는 없어요 (희석·거래정지·공매도·저유통 등).

당일 등락

-3.5%

시가 갭

-1.3%

당일 고가 대비

-2.7%

오늘 거래정지

없음

평소 회전율 (플로트/일)

3.3%

오늘 거래량

5만부분 집계

평소 회전율 = 10일 평균 거래량 ÷ 유통주식. 높을수록 손바뀜이 활발해 단타가 잘 붙어요. 오늘 거래량은 KIS 실시간이 붙으면 전체 거래소 통합, 아니면 무료 피드의 부분 집계예요(옆에 어느 쪽인지 적혀 있어요).

체결가 등락으로 매수/매도 방향을 추정한 근사치예요(tick rule). 규모는 이 종목 자체 거래 분포 기준 — 초대형 = 상위 5% 큰 체결. 최근 정규장 기준.

10일 평균 거래량

964만

3개월 평균 거래량

483만

발행주식수

2.9억주

유통주식 (Float)

—

52주 최고가

—

52주 최저가

—

베타

—

PER (TTM)

—

PBR

—

최근 18개월간 희석 관련 공시가 없어요.

0-100점이에요. 60점을 넘으면 스퀴즈 가능성이 있어요.

공매도 잔고 (유통 대비)

+11.5%

상환일수 (DTC)

3.6일

공매도 거래비중

+70.7%

차입 비용

+0.4%

상환일수 (DTC)

3.6일

당일 공매도 비중

71%

차입료 (CTB)

0%

대여 가능

5.2M주

• 재탕Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)StockTitan1주 전neutral
• Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire1주 전neutral
• Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibodybenzinga2주 전neutral
• Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccinebenzinga2주 전neutral
• Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311StockTitan2주 전호재
• 재탕Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311GlobeNewswire2주 전호재
• Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026benzinga2026.09.01 20:10neutral
• Invivyd Appoints Marc Elia As CEObenzinga2026.09.01 20:08neutral
• Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Targetbenzinga2026.08.27 20:14neutral
• 재탕12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga3주 전neutral

1. 뉴스1주 전 · StockTitan

   Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2. 뉴스1주 전 · GlobeNewswire

   Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3. 뉴스2주 전 · benzinga

   Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

4. 뉴스2주 전 · benzinga

   Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine

5. 뉴스2주 전 · StockTitan

   Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

6. 뉴스2주 전 · GlobeNewswire

   Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

7. 뉴스2026.09.01 20:10 · benzinga

   Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026

8. 뉴스2026.09.01 20:08 · benzinga

   Invivyd Appoints Marc Elia As CEO

9. 뉴스2026.08.27 20:14 · benzinga

   Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target

10. 뉴스3주 전 · benzinga

    12 Health Care Stocks Moving In Monday's Intraday Session

11. 뉴스3주 전 · benzinga

    12 Health Care Stocks Moving In Monday's Pre-Market Session

12. 뉴스2026.09.01 21:06 · benzinga

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

불러오는 중…

분류

분류·메모를 달면 자동으로 관심종목에 담겨요.

불러오는 중…